Updated: DOJ opens criminal probe into Cassava over allegations of Alzheimer's drug data manipulation — report

Paul Schloesser

Associate Editor

Months after reports of allegations regarding Cassava Sciences’ lead drug candidate for Alzheimer’s emerged, the DOJ may now be raising its head to investigate the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: DOJ opens criminal probe into Cassava over allegations of Alzheimer's drug data manipulation — report

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Up­dat­ed: DOJ opens crim­i­nal probe in­to Cas­sa­va over al­le­ga­tions of Alzheimer's drug da­ta ma­nip­u­la­tion — re­port

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Updated: DOJ opens criminal probe into Cassava over allegations of Alzheimer's drug data manipulation — report